ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Th17 Cell Inhibition in a Costimulation Blockade Based Regimen for Vascularized Composite Allotransplantation Using A Non-Human Primate Model

D. P. Moris, A. Atia, M. Rae, M. Song, L. Stempora, F. Leopardi, K. Williams, J. Kwun, W. Parker, A. Cardones, A. D. Kirk, L. C. Cendales

Surgery, Duke, Durham, NC

Meeting: 2020 American Transplant Congress

Abstract number: 509

Keywords: Rejection, Skin transplantation, T cell activation, T helper cells

Session Information

Session Name: Vascularized Composite Allograft

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

*Purpose: Vascularized composite allotransplantation (VCA) is challenged by the morbidity of non-specific immunosuppression required to prevent rejection. The use of highly specific biologics has not been well explored in VCA. Given that psoriasis is T-cell mediated, as is rejection of skin-containing VCAs, we sought to assess the role of two biologics, ustekinumab and secukinumab, which are approved to treat psoriasis by inhibiting Th17 cells.

*Methods: We combined these agents with belatacept and steroids in a VCA non-human primate model. The study included 3 groups. Group I consisted of Belatacept and Steroids, group II was Belatacept, Ustekinumab with steroid taper, and group III was Belatacept, Secukinumab with steroid taper.

*Results: Three animals were transplanted in each group. In group I, the mean graft survival time until the first sign of rejection was 10 days whereas in group II and III it was 10.33 and 11 days respectively. The immunohistochemistry analysis result showed that the number of IL-17a+ cells and the intensity of IL-17a expression were significantly reduced in both dermis and hypodermis parts in groups II and III when compared to group I (P<0.01).

*Conclusions: Ustekinumab and secukinumab led to less T-cell infiltration and IL-17a expression in the allograft but provided no benefit to belatacept and steroids in VCA survival. These pilot data inform the role of Th17 cell inhibition in addition to costimulation molecule-focused therapies to directly targeting the unique components of T-cell mediated rejection of VCA.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Moris DP, Atia A, Rae M, Song M, Stempora L, Leopardi F, Williams K, Kwun J, Parker W, Cardones A, Kirk AD, Cendales LC. Th17 Cell Inhibition in a Costimulation Blockade Based Regimen for Vascularized Composite Allotransplantation Using A Non-Human Primate Model [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/th17-cell-inhibition-in-a-costimulation-blockade-based-regimen-for-vascularized-composite-allotransplantation-using-a-non-human-primate-model/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences